John Valliant, Chief Executive Officer at Fusion Pharmaceuticals Inc. (FUSN), sold 67,596 shares at $7.77 ($526K) on 2022-02-23, disclosed to the SEC on 2022-02-23.
Open-market sale of $526k FUSN by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.88 | 4,898 | $39K | 7.3% |
| 2 | $7.85 | 4,100 | $32K | 6.1% |
| 3 | $7.77 | 29,299 | $228K | 43.3% |
| 4 | $7.77 | 29,299 | $228K | 43.3% |
| Total | $7.78 avg | 67,596 | $526K | 100% |
| Filing → |
| FUSN | SELL | 2022-04-13 | $432K | — | Filing → |
| FUSN | SELL | 2022-04-08 | $16K | — | Filing → |
| FUSN | SELL | 2022-04-05 | $29K | — | Filing → |